MyFinsight
Home
Blog
About
Back
Income Statement
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)
source: myfinsight.com
Comprehensive loss
-$23,757K
(8.95%↑ Y/Y)
Interest and other
income, net
$2,788K
(12.37%↑ Y/Y)
Net loss
-$23,635K
(9.17%↑ Y/Y)
Unrealized loss on
marketable securities
-$122K
Total other income,
net
$2,788K
(12.37%↑ Y/Y)
Roche DACAgreement
$2,666K
Roche Agreement
$2,127K
(10.09%↑ Y/Y)
MKDGAgreement
$1,833K
(-46.53%↓ Y/Y)
Betta Agreement
$15K
(-72.22%↓ Y/Y)
Loss from operations
-$26,423K
(7.29%↑ Y/Y)
Revenue from
collaboration agreements
$6,641K
(2.75%↑ Y/Y)
Total operating
expenses
$33,064K
(-5.43%↓ Y/Y)
Research and development
$24,471K
(-6.59%↓ Y/Y)
General and
administrative
$8,593K
(-1.98%↓ Y/Y)
Back